Published in J Clin Invest on January 01, 1997
Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress. Mol Cell Biol (1993) 5.11
Heat shock proteins and the immune response. Immunol Today (1990) 4.94
Heat shock proteins. J Biol Chem (1990) 3.64
Molecular cloning and expression of a human heat shock factor, HSF1. Proc Natl Acad Sci U S A (1991) 3.47
Heat shock factor and the heat shock response. Cell (1991) 3.35
Induction of the heat shock response reduces mortality rate and organ damage in a sepsis-induced acute lung injury model. Crit Care Med (1994) 2.43
In vitro activation of heat shock transcription factor DNA-binding by calcium and biochemical conditions that affect protein conformation. Proc Natl Acad Sci U S A (1990) 2.28
Heat-shock response is associated with enhanced postischemic ventricular recovery. Circ Res (1988) 2.15
Complex modes of heat shock factor activation. Mol Cell Biol (1990) 1.94
The DNA-binding activity of the human heat shock transcription factor is regulated in vivo by hsp70. Mol Cell Biol (1993) 1.76
Heat shock-induced interactions of heat shock transcription factor and the human hsp70 promoter examined by in vivo footprinting. Mol Cell Biol (1991) 1.65
The regulatory domain of human heat shock factor 1 is sufficient to sense heat stress. Mol Cell Biol (1996) 1.53
Hyperthermia protects against light damage in the rat retina. Science (1988) 1.52
Decreased expression of heat shock protein 70 mRNA and protein after heat treatment in cells of aged rats. Proc Natl Acad Sci U S A (1990) 1.51
Mouse heat shock transcription factors 1 and 2 prefer a trimeric binding site but interact differently with the HSP70 heat shock element. Mol Cell Biol (1993) 1.47
A short element required for turning off heat shock transcription factor: evidence that phosphorylation enhances deactivation. EMBO J (1994) 1.43
Inhibition of the activation of heat shock factor in vivo and in vitro by flavonoids. Mol Cell Biol (1992) 1.40
Arachidonate is a potent modulator of human heat shock gene transcription. Proc Natl Acad Sci U S A (1994) 1.34
Ca2+ is essential for multistep activation of the heat shock factor in permeabilized cells. Mol Cell Biol (1991) 1.24
Mitogen-activated protein kinase acts as a negative regulator of the heat shock response in NIH3T3 cells. Cancer Res (1995) 1.18
Suppression of stress protein GRP78 induction in tumor B/C10ME eliminates resistance to cell mediated cytotoxicity. Cancer Res (1993) 1.17
Stress-induced heat shock protein 70 expression in adrenal cortex: an adrenocorticotropic hormone-sensitive, age-dependent response. Proc Natl Acad Sci U S A (1991) 1.16
Induction of heat shock proteins and their implication in protection against ethanol-induced damage in cultured guinea pig gastric mucosal cells. Gastroenterology (1991) 1.01
Hormone 1 alpha,25-dihydroxyvitamin D3 modulates heat shock response in monocytes. Am J Physiol (1987) 0.96
Isolation of a novel inducible rat heat-shock protein (HSP70) gene and its expression during ischaemia/hypoxia and heat shock. Biochem J (1994) 0.94
Heat shock protein hsp70 accelerates the recovery of heat-shocked mammalian cells through its modulation of heat shock transcription factor HSF1. Proc Natl Acad Sci U S A (1995) 0.93
Induction of heat-shock protein 72 protects against ischemia/reperfusion in rat small intestine. Gastroenterology (1995) 0.93
Activation of heat-shock transcription factor by graded reductions in renal ATP, in vivo, in the rat. J Clin Invest (1994) 0.90
Differential regulation of HSC70, HSP70, HSP90 alpha, and HSP90 beta mRNA expression by mitogen activation and heat shock in human lymphocytes. Exp Cell Res (1991) 0.89
Role of cytosolic Ca2+ and protein kinases in the induction of the hsp70 gene. Kidney Int (1994) 0.88
Increases in HSF1 translocation and synthesis in human epidermoid A-431 cells: role of protein kinase C and [Ca2+]i. J Investig Med (1996) 0.87
HSP-72 synthesis is promoted by increase in [Ca2+]i or activation of G proteins but not pHi or cAMP. Am J Physiol (1994) 0.86
Transcriptional activation of Alzheimer's beta-amyloid precursor protein gene by stress. Brain Res Mol Brain Res (1995) 0.85
Heat shock protects pig kidneys against warm ischemic injury. Transplant Proc (1990) 0.80
Rapid assay of HSF1 and HSF2 gene expression by RT-PCR. Mol Cell Biochem (1996) 0.80
Heat shock inhibits the hypoxia-induced effects on iodide uptake and signal transduction and enhances cell survival in rat thyroid FRTL-5 cells. Thyroid (1996) 0.77
Heat shock increases cytosolic free Ca2+ concentration via Na(+)-Ca2+ exchange in human epidermoid A 431 cells. Am J Physiol (1992) 0.77
Characterization of intracellular calcium pools and their desensitization in thermotolerant human A-431 cells. J Investig Med (1996) 0.76
Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther (1998) 3.36
T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol (1989) 3.10
Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol (2009) 1.95
IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon gamma. Proc Natl Acad Sci U S A (1989) 1.89
Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-8- T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci U S A (1990) 1.83
Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest (1998) 1.80
Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol (2001) 1.68
B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest (1996) 1.56
Clinical use of the measurement of soluble cell adhesion molecules in patients with autoimmune rheumatic diseases. Clin Diagn Lab Immunol (1997) 1.48
Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Clin Immunol Immunopathol (1996) 1.46
Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum (2001) 1.44
Prophylactic use of antibiotics and immunisations in patients with SLE. Ann Rheum Dis (2002) 1.41
Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol (1983) 1.37
TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol (1995) 1.36
Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol (1986) 1.31
Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol (1999) 1.30
Overexpression of the heat shock protein 70 enhances the TCR/CD3- and Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. J Immunol (1997) 1.26
Protein kinase C-theta participates in the activation of cyclic AMP-responsive element-binding protein and its subsequent binding to the -180 site of the IL-2 promoter in normal human T lymphocytes. J Immunol (2001) 1.22
Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum (1997) 1.21
U-73122, an aminosteroid phospholipase C antagonist, noncompetitively inhibits thyrotropin-releasing hormone effects in GH3 rat pituitary cells. Endocrinology (1992) 1.20
Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum (1996) 1.16
IL-17-producing T cells in lupus nephritis. Lupus (2011) 1.15
Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol (2001) 1.14
Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3zeta expression. Blood (2001) 1.13
Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol (2012) 1.12
Deficient gamma-interferon production in patients with systemic lupus erythematosus. Arthritis Rheum (1986) 1.11
Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specific DNA-binding protein. Biochem J (1999) 1.10
Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. Int Immunol (1990) 1.10
Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo. J Immunol (1991) 1.09
ZAP-70 and SLP-76 regulate protein kinase C-theta and NF-kappa B activation in response to engagement of CD3 and CD28. J Immunol (2001) 1.08
Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus (2009) 1.08
Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol (1988) 1.08
The effect of olive oil and fish consumption on rheumatoid arthritis--a case control study. Scand J Rheumatol (1991) 1.06
NIH conference. Systemic lupus erythematosus. Ann Intern Med (1991) 1.06
Human in vitro allogeneic responses. Demonstration of three pathways of T helper cell activation. J Immunol (1990) 1.03
Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) (1981) 1.02
Altered signal transduction in SLE T cells. Rheumatology (Oxford) (2007) 1.02
T cell-antigen-presenting cell interactions in human systemic lupus erythematosus. Evidence for heterogeneous expression of multiple defects. J Immunol (1993) 1.02
Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J Clin Invest (1985) 1.01
Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol (1993) 1.00
CAMP response element modulator a expression in patients with systemic lupus erythematosus. Lupus (2006) 1.00
Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription. J Clin Invest (1991) 1.00
Natural killer cells and interferon responses in patients with systemic lupus erythematosus. Clin Exp Immunol (1982) 0.99
NIH conference. Lupus nephritis. Ann Intern Med (1987) 0.99
Defective production of functional 98-kDa form of Elf-1 is responsible for the decreased expression of TCR zeta-chain in patients with systemic lupus erythematosus. J Immunol (2002) 0.98
Overexpression of HSP-70 inhibits the phosphorylation of HSF1 by activating protein phosphatase and inhibiting protein kinase C activity. FASEB J (1998) 0.96
Increased proto-oncogene expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum (1986) 0.96
Cellular immune responses in systemic lupus erythematosus. Prog Allergy (1984) 0.95
Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations. Clin Exp Rheumatol (1996) 0.95
Chronic lupus peritonitis with ascites. Ann Rheum Dis (1991) 0.94
Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine. Clin Immunol (1999) 0.93
Heterogeneous nuclear ribonucleoprotein D0 contains transactivator and DNA-binding domains. Biochem J (2000) 0.93
T cell signaling abnormalities in systemic lupus erythematosus are associated with increased mutations/polymorphisms and splice variants of T cell receptor zeta chain messenger RNA. Arthritis Rheum (2001) 0.93
Defective FcgammaRIIb1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus. Clin Immunol (2001) 0.91
Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol (1993) 0.91
Spontaneous and pokeweed mitogen-induced plaque-forming cells in systemic lupus erythematosus. Clin Immunol Immunopathol (1981) 0.90
Prevalence of T cell receptor zeta chain deficiency in systemic lupus erythematosus. Lupus (2003) 0.89
Increased expression of functional Fas-ligand in activated T cells from patients with systemic lupus erythematosus. Autoimmunity (1997) 0.89
Pharmacological characterization of endothelin-stimulated phosphoinositide breakdown and cytosolic free Ca2+ rise in rat C6 glioma cells. J Neurosci (1992) 0.89
Association of deficient type II protein kinase A activity with aberrant nuclear translocation of the RII beta subunit in systemic lupus erythematosus T lymphocytes. J Immunol (2000) 0.89
Corticotropin-releasing factor inhibits neurogenic plasma extravasation in the rat paw. J Pharmacol Exp Ther (1986) 0.89
Effects of cholera toxin on human B cells. Cholera toxin induces B cell surface DR expression while it inhibits anti-mu antibody-induced cell proliferation. J Immunol (1990) 0.89
The association of systemic lupus erythematosus and myasthenia gravis. Postgrad Med J (1994) 0.89
Muscle involvement in systemic lupus erythematosus. JAMA (1981) 0.88
Increases in HSF1 translocation and synthesis in human epidermoid A-431 cells: role of protein kinase C and [Ca2+]i. J Investig Med (1996) 0.87
Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. J Allergy Clin Immunol (1986) 0.87
Transcriptional regulation of the complement receptor 2 gene: role of a heterogeneous nuclear ribonucleoprotein. J Immunol (1997) 0.87
Cross-linking of the Fas/APO-1 antigen suppresses the CD3-mediated signal transduction events in human T lymphocytes. J Immunol (1995) 0.87
CD28 expression on T cell subsets in vivo and CD28-mediated T cell response in vitro in patients with rheumatoid arthritis. Arthritis Rheum (1995) 0.87
Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis. Clin Immunol Immunopathol (1990) 0.86
Elevated in vivo expression of the costimulatory molecule B7-BB1 (CD80) on antigen presenting cells from a patient with SLE. Clin Exp Rheumatol (1997) 0.86
Suppressor T cells in systemic lupus erythematosus: lack of defective in vitro suppressor cell generation in patients with active disease. J Clin Lab Immunol (1982) 0.86
A clinical and pathologic study of cerebrovascular disease in patients with systemic lupus erythematosus. Semin Arthritis Rheum (1986) 0.86
Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders. Clin Exp Immunol (1986) 0.86
Regulation of immunoglobulin secretion by factor H of human complement. Immunology (1985) 0.85
Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event. J Pediatr (1990) 0.85
Phospholipase C activation by Na+/Ca2+ exchange is essential for monensin-induced Ca2+ influx and arachidonic acid release in FRTL-5 thyroid cells. J Investig Med (1999) 0.85
Quinolinic acid in patients with systemic lupus erythematosus and neuropsychiatric manifestations. J Rheumatol (1996) 0.84
Multiple transcription factors regulate the inducible expression of the human complement receptor 2 promoter. J Immunol (2001) 0.84
Pituitary-adrenal responsiveness to corticotropin-releasing hormone in patients receiving chronic, alternate day glucocorticoid therapy. J Clin Endocrinol Metab (1985) 0.84
Type C retroviruses of the human T cell leukemia family are not evident in patients with systemic lupus erythematosus. Arthritis Rheum (1986) 0.84
Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis. Clin Diagn Lab Immunol (1997) 0.84
Monoclonal antibody-directed radioimmunoassay detects cytochrome P-450 in human placenta and lymphocytes. Science (1985) 0.84
Lupus nephritis and other autoimmune features in patients with diabetes mellitus due to autoantibody to insulin receptors. Ann Intern Med (1985) 0.84
Dexamethasone modulates TCR zeta chain expression and antigen receptor-mediated early signaling events in human T lymphocytes. Cell Immunol (2001) 0.83
COX-2 inhibitors are contraindicated for treatment of combined injury. Radiat Res (2009) 0.83
Cytotoxic antibodies to natural killer cells in systemic lupus erythematosus. Clin Immunol Immunopathol (1982) 0.83
Interleukin-2 restores the depressed allogeneic cell-mediated lympholysis and natural killer cell activity in patients with systemic lupus erythematosus. Clin Immunol Immunopathol (1985) 0.83
A systemic lupus erythematosus gene expression array in disease diagnosis and classification: a preliminary report. Lupus (2010) 0.83
Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin Exp Rheumatol (1994) 0.83
Complement receptor 2 in the regulation of the immune response. Clin Immunol Immunopathol (1998) 0.82
T and B lymphocyte function in patients with lupus nephritis: correlation with renal pathology. Clin Nephrol (1984) 0.82
A novel isoform of the orphan receptor RORγt suppresses IL-17 production in human T cells. Genes Immun (2012) 0.81
Purinergic (P2) receptor-operated calcium entry into rat thyroid cells. Biochem Biophys Res Commun (1993) 0.81
The estrogen-inducible transferrin receptor-like membrane glycoprotein is related to stress-regulated proteins. J Biol Chem (1994) 0.81
Opioids acting through delta receptors elicit a transient increase in the intracellular free calcium concentration in dorsal root ganglion-neuroblastoma hybrid ND8-47 cells. J Pharmacol Exp Ther (1994) 0.81